Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

To Evaluate the Effect of Denosumab in Lumbar Spine Bone Mineral Density (BMD) Z-score at 12 Months, as Assessed by Dual-energy X-ray Absorptiometry (DXA), in Children 2 to 17 Years of Age (at the Time of Screening) on a 3-Month Dosing Regimen With OI

NCT02352753 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT02352753
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02352753 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
To Evaluate the Effect of Denosumab in Lumbar Spine Bone Mineral Density (BMD) Z-score at 12 Months, as Assessed by Dual-energy X-ray Absorptiometry (DXA), in Children 2 to 17 Years of Age (at the Time of Screening) on a 3-Month Dosing Regimen With OI
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Terminated
Start date
June 24, 2015
Completion date
March 26, 2022
Enrollment
153 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

osteogenesis imperfecta